1009 completed. 1009 Phase 2, 175 Phase 1, 41 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1009 | Completed 1009 |
| Phase 1 | 175 | Completed 175 |
| Phase 3 | 41 | Completed 41 |
Follow Prostatic Diseases: new trials by email Literature Review of Prostatic Diseases trials Research Report on Prostatic Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| RADA16 for Aquablation Day Case PuraStat - Hematuria, Benign Prostatic Hyperplasia | Phase 2 | Completed | NYU Langone Health | 24 | 2026-05-14 | 2026-11-09 |
| Safety and Efficacy of PSMA-Targeted Fluorescent Contrast Agent DGPR1008 for Intraoperative Imaging in Robot-Assisted Radical Prostatectomy 0.02 mg/kg of DGPR1008 Injection was administered 24 hours before surgery, 0.04 mg/kg of DGPR1008 Injection was administered 24 hours before surgery, 0.06 mg/kg of DGPR1008 Injection was administered 24 hours before surgery - Prostate Cancer | Phase 2 | Completed | Zhu Yinjie | 18 | 2026-03-20 | 2026-09-30 |
| Enhancing Readability of Lay Abstracts and Summaries for Medical Knowledge Using Generative Artificial Intelligence (BRIDGE AI 3) Pub2Post - Prostate Cancer (Adenocarcinoma), Bladder Cancer | Phase 2 | Completed | University of Southern California | 120 | 2025-01-16 | 2026-05-06 |
| Buffered Lidocaine for Reducing Pain in Patients Undergoing Prostate Biopsy, BURN Trial Buffered Lidocaine (1% Lidocaine + 8.4% Sodium Bicarbonate, in a 3:1 ratio), Lidocaine, Biopsy of Prostate - Prostate Cancer | Phase 1 / Phase 2 | Completed | University of Washington | 350 | 2025-01-09 | 2026-02-17 |
| Comparative Performance of 64Copper [64Cu]-SAR-bis-PSMA vs 68Ga PSMA-11 PET CT for the Detection of Prostate Cancer Recurrence in the Setting of Biochemical Failure Following Radical Prostatectomy 64Cu-SAR-bisPSMA - Prostate Cancer (Post Prostatectomy) | Phase 2 | Completed | St Vincent's Hospital, Sydney | 50 | 2024-11-21 | 2026-08-14 |
| 68Ga-P16-093 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI 68Ga-P16-093 - Prostate Cancer (Adenocarcinoma) | Phase 2 | Completed | First Affiliated Hospital of Fujian Medical University | 82 | 2024-10-01 | 2026-10-23 |
| CYTALUX™for the Intraoperative Imaging of Prostate Cancer Cytalux™ (pafolacianine) for fluorescent imaging, Image Guided Surgery - Prostate Cancer | Phase 2 | Completed | Indiana University | 9 | 2024-09-19 | 2026-06-01 |
| Pharmacokinetics, Biodistribution, Radiation Dose and Safety Study of 68Ga-NYM032 in Patients 68Ga-NYM032 injection - Prostate Cancer | Phase 1 / Phase 2 | Completed | Norroy Bioscience Co., LTD | 20 | 2024-06-04 | 2025-05-21 |
| A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer Debio 4228 - Prostate Cancer | Phase 2 | Completed | Debiopharm International SA | 55 | 2024-05-23 | 2026-08-24 |
| Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer EPI-7386, Enzalutamide, Androgen Deprivation Therapy (ADT) - Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Prostate Cancer | Phase 2 | Completed | Pedro Barata, MD, MSc | 13 | 2024-05-16 | 2025-05-29 |
| Study to Evaluate a New Method to Detect Residual Tumours During Surgery for Prostate Cancer Using Confocal Microscopy NeuroSAFE procedure, LaserSAFE procedure - Prostate Cancer | Phase 1 / Phase 2 | Completed | University College, London | 21 | 2024-05-15 | 2025-01-10 |
| Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer Biopsy, Biospecimen Collection, Computed Tomography - Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 | Completed | Mayo Clinic | 7 | 2024-03-08 | 2026-06-09 |
| A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer lorigerlimab, docetaxel, Prednisone - Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Neoplasms | Phase 2 | Completed | MacroGenics | 154 | 2023-09-28 | 2026-05-22 |
| ArtemiCoffee in Patients With Rising PSA ArtemiCoffee - Prostate Cancer | Phase 2 | Completed | Zin W Myint | 20 | 2023-08-11 | 2026-08-11 |
| IS-002 Phase 2 Prostate Cancer Study Administration of IS-002, Firefly fluorescent imaging, robotic-assisted laparoscopic prostatectomy with pelvic lymph node dissection - Prostate Cancer | Phase 2 | Completed | Intuitive Surgical | 59 | 2023-06-16 | 2025-09-04 |
| A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors SNS-101 (anti-VISTA), Cemiplimab - Solid Tumor, Adult, Advanced Solid Tumor | Phase 1 / Phase 2 | Completed | Sensei Biotherapeutics, Inc. | 98 | 2023-05-31 | 2026-09-02 |
| EvaluatioN of HIFU Hemiablation and Short Term AndrogeN Deprivation Therapy Combination to Enhance Prostate Cancer Control. HIFU hemi-ablation combined with ADT. - Prostate Cancer, Androgen Deprivation Therapy | Phase 2 | Completed | Institut Mutualiste Montsouris | 19 | 2023-03-07 | 2026-10-02 |
| A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) KVA12123 - Dose Escalation, KVA12123 Plus Pembrolizumab - Dose Escalation, KVA12123 - Dose Expansion - Cancer, Solid Tumor | Phase 1 / Phase 2 | Completed | Kineta Inc. | 40 | 2023-03-03 | 2026-10-05 |
| The Additive Value of Pyridostigmine to Silodosin in Acute Urinary Retention silodosin 8 mg capsule and the pyridostigmine bromide 60 mg tablet, silodosin 8 mg capsule - Prostatic Hyperplasia | Phase 2 | Completed | Beni-Suef University | 140 | 2023-02-01 | 2024-03-20 |
| Perioperative Propranolol During Prostatectomy to Decrease Cancer Recurrence Propranolol - Prostate Cancer | Phase 2 | Completed | Oslo University Hospital | 40 | 2023-01-02 | 2024-05-29 |
Showing 20 of 1009. Sign in to see all of them.
Prostatic Neoplasms (946) · Prostatic Hyperplasia (54) · Neoplasms (50) · Neoplasm Metastasis (46) · Breast Neoplasms (29) · Carcinoma, Non-Small-Cell Lung (18) · Lung Neoplasms (17) · Ovarian Neoplasms (16) · Urinary Bladder Neoplasms (16) · Colorectal Neoplasms (14) · Melanoma (12) · Colonic Neoplasms (11) · Uterine Cervical Neoplasms (11) · Esophageal Neoplasms (10) · Pancreatic Neoplasms (10)
Urogenital Diseases (1007) · Genital Diseases (1006) · Genital Diseases, Male (1006) · Male Urogenital Diseases (1003) · Neoplasms by Site (945) · Genital Neoplasms, Male (942) · Urogenital Neoplasms (942) · Neoplasms (900) · Pathological Conditions, Signs and Symptoms (90) · Pathologic Processes (63) · Neoplastic Processes (49) · Female Urogenital Diseases (43) · Female Urogenital Diseases and Pregnancy Complications (43) · Neoplasms by Histologic Type (38)
Docetaxel (102) · Prednisone (85) · Leuprolide (49) · Abiraterone Acetate (48) · enzalutamide (46) · bicalutamide (38) · Goserelin (36) · Radiotherapy (27) · Estramustine (23) · acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide (22) · gallium 68 PSMA-11 (19) · abiraterone (17) · Carboplatin (16) · Magnetic Resonance Spectroscopy (15) · apalutamide (15)
National Cancer Institute (NCI) (77) · Memorial Sloan Kettering Cancer Center (30) · M.D. Anderson Cancer Center (22) · University Health Network, Toronto (22) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (18) · Dana-Farber Cancer Institute (17) · Alliance for Clinical Trials in Oncology (14) · University of Washington (14) · Astellas Pharma Inc (13) · Ferring Pharmaceuticals (13) · AstraZeneca (12) · Bayer (12) · Eli Lilly and Company (12) · Barbara Ann Karmanos Cancer Institute (11) · University of California, San Francisco (11)
United States (695) · Canada (116) · United Kingdom (65) · France (58) · Germany (40) · Italy (37) · Belgium (34) · Spain (33) · Netherlands (28) · Australia (22) · Czechia (20) · Denmark (20) · Finland (19) · Poland (17) · Russia (16)
Mary-Ellen Taplin, MD (10) · Michael Morris, MD (7) · Ravi A Madan, M.D. (7) · Chadi Nabhan, MD (5) · David C. Smith, MD (5) · Christopher Logothetis, MD (4)
PMID 24722180, PMID 25712310, PMID 18777528, PMID 19455472, PMID 21106711, PMID 21791356, PMID 21802835, PMID 22894553, PMID 23533230, PMID 24510426, PMID 24772219, PMID 24974051, PMID 25475068, PMID 25614256, PMID 25687533, PMID 25786708, PMID 25963190, PMID 26659347, PMID 30189902, PMID 32994091, PMID 33270906, PMID 33465252, PMID 34529005, PMID 35027313, PMID 36001857, PMID 37058234, PMID 37482512, PMID 37496366, PMID 39074346, PMID 41044356, PMID 42186347, PMID 10661346, PMID 11106233, PMID 11586207, PMID 11828001, PMID 11839651, PMID 11905923, PMID 12142053, PMID 12506177, PMID 12610188, PMID 12627508, PMID 12694838, PMID 12893330, PMID 14504052, PMID 14529764, PMID 14669278, PMID 14727242, PMID 14871968, PMID 14967428, PMID 15054447
U10CA031946 (9), P30CA022453 (8), 2017 (7), P30CA016672 (6), 2008 (5), 2016 (5), P30CA015704 (5), P30CA043703 (5), U10CA021115 (5), U10CA032102 (5), N01CM62201 (4), N01CM62206 (4), P30CA015083 (4), P30CA023074 (4), U01CA062491 (4)